Calendar

We are still working on this calendar feature. When fully operational we look forward to having upcoming stock catalyst.

You can Use the “Category” drop down to choose between Phase1, Phase2, Phase3 or PDUFA FDA approval catalysts.

If you have an idea, you are welcome to comment or contact us directly.


Sharing is Caring:
Sun Mon Tue Wed Thu Fri Sat
1
AVEO Pharmaceuticals Inc – AVEO
AVEO Pharmaceuticals Inc – AVEO
Apr 1 – Jun 30 all-day
AVEO Pharmaceuticals Inc – AVEO Top-line data due 2Q 2018 for TIVO-3 – tivozanib Third line treatment of patients with renal cell cancer. Phase 3 completion of enrollment noted June 20, 2017. Futility analysis released … Continue reading "AVEO Pharmaceuticals Inc – AVEO"
Exelixis Inc – EXEL
Exelixis Inc – EXEL
Apr 1 – Jun 30 all-day
Exelixis Inc, EXEL, has Phase 3 data due 1H 2018. Drug: IMblaze370 – cobimetinib and atezolizumab Third-line advanced or metastatic colorectal cancer
MEI Pharma inc – MEIP
MEI Pharma inc – MEIP
Apr 1 – Jun 30 all-day
MEI Pharma inc – MEIP Has 3 upcoming catalyst in 2Q 2018: Pracinostat in combination with Vidaza High-risk Myelodysplastic Syndrome (MDS) Phase 2 commencement of dosing announced June 14, 2017 – data from first stage … Continue reading "MEI Pharma inc – MEIP"
Pluristem Therapeutics Inc – PSTI
Pluristem Therapeutics Inc – PSTI
Apr 1 – Jun 30 all-day
Pluristem Therapeutics Inc (PSTI) has Phase 2 data due to be published 2Q 2018. PLX-PAD (stem cells) Intermittent claudication, or IC [stockdio-historical-chart symbol=”PSTI” stockExchange=”NYSE” displayPrices=”candlestick” width=”580″ height=”380″ days=”90″ motif=”financial” palette=”financial-light”]
2
Achaogen Inc – AKAO
Achaogen Inc – AKAO
May 2 all-day
Achaogen Inc – AKAO Plazomicin – Complicated urinary tract infections (cUTI) Phase 3 data released December 12, 2016 – primary endpoint met. PDUFA date under priority review June 25, 2018. Date appears to have changed … Continue reading "Achaogen Inc – AKAO"
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Eleven Biotherapeutics, Inc – EBIO Phase 3
Eleven Biotherapeutics, Inc – EBIO Phase 3
May 21 all-day
Eleven Biotherapeutics, Inc – EBIO has phase 3 preliminary data due May 21, 2018 for: Vicinium Non-muscle invasive bladder cancer (NMIBC) Phase 3 completion of enrollment announced March 12, 2018 with preliminary data due May 21, … Continue reading "Eleven Biotherapeutics, Inc – EBIO Phase 3"
22
23
24
25
26
27
28
29
30
31
Kitov Pharma Ltd – KTOV PDUFA date for KIT-302
Kitov Pharma Ltd – KTOV PDUFA date for KIT-302
May 31 all-day
Kitov Pharma Ltd – KTOV has a PDUFA date May 31, 2018. KIT-302 Osteoarthritis and Hypertension [stockdio-historical-chart symbol=”KTOV” stockExchange=”NYSE” displayPrices=”candlestick” width=”580″ height=”380″ days=”90″ motif=”financial” palette=”financial-light”]

Leave a Reply

Your email address will not be published. Required fields are marked *